ReviewCNS drugs2010
Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.
Review in CNS drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- A systematic review and meta-analysis on impulse-control disorders in patients with pituitary adenomas exposed to dopamine agonists.Frontiers in endocrinology · 2026Pooled it
- Effects of different types of deep brain stimulation on gait disorders in patients with Parkinson's disease: a network meta-analysis of randomized controlled trials.Frontiers in aging neuroscience · 2025Pooled it
- Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.CNS neuroscience & therapeutics · 2017Pooled it
- Pooled it
- Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson's disease in China: a randomized clinical trial.BMC complementary medicine and therapies · 2025Trial
- Trial
- Pharmacological interventions for peripartum cardiomyopathy.The Cochrane database of systematic reviews · 2024Article
- Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease.Brain sciences · 2024Review
- Pre-clinical Aspects and Contemporary Treatments of Parkinson's Disease.CNS & neurological disorders drug targets · 2024Review
- Derivation of the multiply-branched ergot alkaloid pathway of fungi.Microbial biotechnology · 2023Review
- Review
- Construction of an efficientFrontiers in bioengineering and biotechnology · 2022Article
- A Baeyer-Villiger Monooxygenase Gene Involved in the Synthesis of Lysergic Acid Amides Affects the Interaction of the Fungus Metarhizium brunneum with Insects.Applied and environmental microbiology · 2021Article
- Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.Biomolecules · 2021Review
- Stability Evaluation of Brain Changes in Parkinson's Disease Based on Machine Learning.Frontiers in computational neuroscience · 2021Article
- Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.PloS one · 2021Article
- L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson's Disease.Experimental neurobiology · 2020Article
- Several Metarhizium Species Produce Ergot Alkaloids in a Condition-Specific Manner.Applied and environmental microbiology · 2020Article
- Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review.BMC neurology · 2018Review
- Schizophrenia as Potential Trigger for Melanoma Development and Progression! The Psycho-Neuro-Endocrine-Oncology (P.N.E.O) Network!Open access Macedonian journal of medical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dopamine receptor agonists are indicated for the symptomatic treatment of early, moderate or advanced Parkinson's disease as well as for the reduction of levodopa-related motor complications. Ergolinic dopamine agonists, such as bromocriptine or pergolide, were initially developed and marketed, and then non-ergolinic dopamine agonists, such as pramipexole and ropinirole, were introduced, reducing the risk of drug-induced fibrotic reactions. Once-daily, controlled-release oral and transdermal formulations have been developed aiming at providing more stable 24-hour plasma drug concentrations and more convenient administration. A disease-modifying effect of dopamine agonists has not been demonstrated clinically. As with any other drug, dopamine agonists can also cause adverse drug reactions, which can be related or unrelated to dopaminergic hyperactivation. Dopaminergic reactions include nausea, hallucinations, confusion and orthostatic hypotension, among others, which were readily identified in pre-marketing clinical trials. During post-marketing surveillance, important adverse reactions were identified, such as daytime somnolence, impulse-control disorders and heart valve fibrosis. Other issues, including the efficacy of dopamine agonists for the treatment of non-motor symptoms, remain under evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.